Why the study?
The effects of pomegranate-derived exosome-like nanovesicles on nonalcoholic fatty liver disease were unknown.
Do pomegranate-derived exosome-like nanovesicles improve nonalcoholic fatty liver disease in preclinical models?
Do pomegranate-derived exosome-like nanovesicles improve nonalcoholic fatty liver disease in preclinical models?
Pomegranate-derived exosome-like nanovesicles demonstrate therapeutic potential for NAFLD by alleviating mitochondrial dysfunction in preclinical models.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for nanovesicle therapy in NAFLD models; leaves open human translation pending trials.
Plant-derived exosome-like nanovesicles carry a variety of bioactive substances and have multiple health benefits. Pomegranate (Punica granatum) is a popular fruit with hepatoprotective effects. However, the effects of pomegranate-derived exosome-like nanovesicles (PENs) on nonalcoholic fatty liver disease (NAFLD) are still unknown. Here, PENs were successfully isolated and characterized, and found to be internalized by HepG2 cells. Interestingly, PENs survived gastrointestinal environment and ameliorated lipid accumulation as well as mitochondrial dysfunction in palmitic acid (PA)-treated HepG2 cells. Importantly, oral administration of PENs accumulated in the liver of mice and effectively alleviated high-fat diet (HFD)-induced NAFLD by improving mitochondrial function, as evidenced by improvements of ATP content, mitochondrial complex I activity and oxidative stress. Moreover, PENs restored SIRT3/SOD2 signaling and improved SOD2 activity in the liver of HFD-fed mice. These findings provide new mechanistic insights into pomegranate’s hepatoprotection and demonstrate the therapeutic potential of PENs for NAFLD.
No takes yet. Share an insight, caveat, or question.
Hou et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: